Mirum Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mirum Pharmaceuticals, Inc.
CDER hit a high mark with 27 first-in-class approvals in the 50 novel agents cleared in 2021.
CanBridge public listing is expected to generate much needed funding and spotlights a largely untapped but challenging segment.
Only three planned marketing authorization applications are known to have been granted accelerated assessment status by the European Medicines Agency between July and October this year.
Marketing applications for 10 new drugs have been added to the latest list of products under review by the European Medicines Agency.
- Specialty Pharmaceuticals